Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

GLOFITAMAB-GXBM for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 38 adverse event reports in the FDA FAERS database where GLOFITAMAB-GXBM was used for Diffuse large b-cell lymphoma refractory.

Most Reported Side Effects for GLOFITAMAB-GXBM

Side Effect Reports % Deaths Hosp.
Cytokine release syndrome 107 21.5% 16 41
Disease progression 68 13.7% 40 13
Off label use 68 13.7% 9 17
Death 67 13.5% 67 6
Pyrexia 45 9.0% 12 8
No adverse event 28 5.6% 0 0
Immune effector cell-associated neurotoxicity syndrome 25 5.0% 13 18
Infection 20 4.0% 11 13
Pneumonia 14 2.8% 9 3
Condition aggravated 12 2.4% 11 0
Covid-19 10 2.0% 4 3
Drug ineffective 10 2.0% 4 2
Sepsis 10 2.0% 5 5
Diffuse large b-cell lymphoma recurrent 9 1.8% 0 1
Dyspnoea 9 1.8% 2 5

Other Indications for GLOFITAMAB-GXBM

Diffuse large b-cell lymphoma (313) Product used for unknown indication (55) B-cell lymphoma (20) Mantle cell lymphoma (18) Diffuse large b-cell lymphoma recurrent (10) Follicular lymphoma (7) Burkitt's lymphoma (6) Lymphoma (6) Lymphoma transformation (5)

Other Drugs Used for Diffuse large b-cell lymphoma refractory

RITUXIMAB (667) EPCORITAMAB-BYSP (353) AXICABTAGENE CILOLEUCEL (336) BENDAMUSTINE (283) CYCLOPHOSPHAMIDE (226) POLATUZUMAB VEDOTIN (223) ETOPOSIDE (165) POLATUZUMAB VEDOTIN-PIIQ (158) GEMCITABINE (147) LENALIDOMIDE (143)

Related Pages

GLOFITAMAB-GXBM Full Profile All Diffuse large b-cell lymphoma refractory Drugs GLOFITAMAB-GXBM Demographics GLOFITAMAB-GXBM Timeline